ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd
Evaluate the Efficacy and Safety of ARX788 in Patients With HER2-positive Advanced Breast Cancer Whose Disease Has Progressed Following T-DXd Therapy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Jian Zhang, MD,PhD
- Phone Number: 85000 +8664175590
- Email: syner2000@163.com
Study Contact Backup
- Name: Yanchun Meng, MD
- Phone Number: 85000 +8664175590
- Email: ycmnankai@126.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18 to 75 years old (including upper and lower limits), male or female;
- Unresectable locally advanced, recurrent or metastatic BC;
- Tissue samples determined to be HER2 positive (defined as IHC3+ or FISH+);
- Received T-DXd treatment in the advanced stage;
- Adequate bone marrow, liver, kidney and coagulation function;
- Voluntarily sign the informed consent, have good compliance and are willing to comply with the follow-up visit.
Exclusion Criteria:
- With meningeal metastases or disseminated brain metastases or active brain metastases;
- Has interstitial lung disease requiring steroid therapy, a history of drug-induced interstitial lung disease, a history of radiation pneumonitis, or any evidence indicating clinically active interstitial lung disease;
- Has any eye disease that require medical intervention such as keratitis, corneal diseases or active eye infection;
- Has cardiac insufficiency;
- Has received any systemic anti-tumor therapy (with the exception of endocrine therapy, with an interval of at least 7 days) within 28 days (or at least 5 half-lives) before the first use of the investigational product;
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: ARX788
ARX788,1.5 mg/kg IV infusion on Day 1 of each 21-day treatment cycle
|
ARX788,1.5 mg/kg IV infusion on Day 1 of each 21-day treatment cycle
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Objective remission rate (ORR)
Time Frame: Until progression, assessed up to approximately 24 months
|
The proportion of patients who have a CR or PR, as determined by the Investigator at local site per RECIST 1.1.
|
Until progression, assessed up to approximately 24 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Disease control rate (DCR)
Time Frame: Baseline through end of study, assessed up to 24 months]
|
The proportion of patients who have a CR or PR or SD, as determined by the Investigator at local site per RECIST 1.1.
|
Baseline through end of study, assessed up to 24 months]
|
|
Duration of relief (DOR)
Time Frame: Until progression, assessed up to approximately 24 months
|
Time from the date of first documented response until the date of documented progression or death in the absence of disease progression
|
Until progression, assessed up to approximately 24 months
|
|
Progression-free survival (PFS)
Time Frame: Until progression or death, assessed up to approximately 36 months]
|
Time to progression as assessed by the Investigator at local site per RECIST 1.1, or death due to any cause.
|
Until progression or death, assessed up to approximately 36 months]
|
|
Overall survival (OS)
Time Frame: Until death, assessed up to approximately 50 months
|
Time to death due to any cause
|
Until death, assessed up to approximately 50 months
|
|
The number of subjects experiencing adverse event TEAEs
Time Frame: Up to follow-up period, approximately 50 months
|
Occurrence of AEs according to CTCAE v5.0
|
Up to follow-up period, approximately 50 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ACE-Breast-10
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.